PDL BioPharma, Inc.
PDLIDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Multiple Sclerosis
M200 (volociximab) in Combination with Dacarbazine (DTIC)
Melanoma
Visilizumab
Severe Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | Phase 2 | Multiple Sclerosis | - | - |
M200 (volociximab) in Combination with Dacarbazine (DTIC) | Phase 2 | Melanoma | - | - |
Visilizumab | Phase 2 | Severe Ulcerative Colitis | - | - |
Frequently asked questions
What is in PDL BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in PDL BioPharma, Inc.'s (PDLI) pipeline across Phase 2. Its lead program is Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is PDL BioPharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for PDL BioPharma, Inc. (PDLI) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PDLI biotech catalysts?→
Add PDLI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow PDL BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.